Question Of The Day

Question - What drug of abuse was developed by a German pharmaceutical company in 1912, originally known as “Methylsafrylaminc” and was intended as a parent compound to synthesize medications that control bleeding?

Question - What mushroom toxin has been associated with delayed (36 hours to 3 weeks following ingestion) renal injury and possible renal failure?

Question - Onset of the so-called Antabuse reaction may begin after alcohol is consumed by a person who has ingested inky cap mushrooms (Coprinopsis atramentaria). How long following alcohol consumption after eating inky caps can this Antabuse reaction be triggered?

Question - How long can urushiol, the sap oil of poison ivy, remain active on the surface of objects?

Question - When exposure to burning poisonous plants is unavoidable, employers should provide workers with what form of respiratory protection?

Question - What is the so-called “HAZWOPER” program?

Question - What are the so-called GenX chemicals?

Question - PD-1/PD-L1 inhibitors have recently been approved for the treatment of a number of malignancies. The use of PD-1 axis inhibition is drastically changing the use of immunotherapy in cancer. What are the novel immune related adverse effects associated with the use of these agents?

Question - The article cited below reports the drug “Dexmedetomidate induces sedation while preserving a degree of arousability among patients in the intensive care unit (ICU), and its use has resulted in a shorter time to extubation, an increased number of days free from coma or delirium, a reduced incidence of agitated delirium, prevention of delirium, and lower mortality than other agents administered in certain populations.” What adverse effects are reported in association with the administration of dexmedetomidate?

Question - What factors account for the summer seasonal peak of Cryptosporidium related infections?